Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Topical Trimebutine on Pain After Hemorrhoidectomy

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2017 by Mansoura University
Information provided by (Responsible Party):
Sameh Emile, Mansoura University Identifier:
First received: January 24, 2017
Last updated: January 26, 2017
Last verified: January 2017
Trimebutine acts through smooth muscle relaxation. It is presumed that the topical application of trimebutine after hemorrhoidectomy may help relieve pain after the procedure by relaxing the internal anal sphincter spasm.

Condition Intervention
Drug: Trimebutine
Procedure: Hemorrhoidectomy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Effect of Trimebutine on Postoperative Pain After Milligan-Morgan Hemorrhoidectomy: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Mansoura University:

Primary Outcome Measures:
  • Pain assessment assessed using visual analogue score from 0-10 [ Time Frame: Pain will be assessed at 12 hours after the procedure ]
    Anal pain will be assessed using visual analogue score from 0-10

Estimated Enrollment: 42
Anticipated Study Start Date: February 1, 2017
Estimated Study Completion Date: April 1, 2018
Estimated Primary Completion Date: February 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Hemorrhoidectomy
Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
Procedure: Hemorrhoidectomy
Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
Active Comparator: trimebutine
Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
Drug: Trimebutine
Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
Other Name: Gastreg suppository
Procedure: Hemorrhoidectomy
Patients will undergo classic Milliagn-Morgan hemorrhoidectomy

Detailed Description:
A randomized trial will be carried out to investigate the effect of trimebutine on pain after Milligan-Morgan hemorrhoidectomy. Trimebutine relaxes the internal anal sphincter spasm which usually occurs after excisional hemorrhoidectomy.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of both genders aging between 18-70 years with grade III/VI internal hemorrhoids will be included

Exclusion Criteria:

  • Patients with grade I/II internal hemorrhoids or external hemorrhoids.
  • Patients with associated anorectal pathology such as anal fissure, anal fistula, rectal prolapse, neoplasm, solitary rectal ulcer, and inflammatory bowel diseases.\
  • Patients with recurrent hemorrhoids after previous surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03036111

Contact: Sameh H Emile, M.D

Mansoura university hospital
Mansoura, Dakahlia, Egypt
Sponsors and Collaborators
Mansoura University
Principal Investigator: Sameh H Emile, M.D. Mansoura University
  More Information

Responsible Party: Sameh Emile, Lecturer of general surgery, Mansoura University Identifier: NCT03036111     History of Changes
Other Study ID Numbers: mansourau20172
Study First Received: January 24, 2017
Last Updated: January 26, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Gastrointestinal Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on April 27, 2017